News
Genentech announced that the Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities.
News
Formulation does not require reconstitution, reducing the potential for dosing errors
News
The approval of Imfinzi is based on the positive PFS data from the Phase 3 PACIFIC trial.
News
Keytruda, a programmed death receptor-1 (PD-1)-blocking antibody, recently gained approval for urothelial carcinoma and metastatic non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
The NDA proposes the use of ready-to-dilute pemetrexed injection for the treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and mesothelioma (in combination with cisplatin).
News
Qiagen announced that it has received marketing approval for its therascreen EFGR RGQ PCR Kit as a companion diagnostic to Iressa (geftinib; AstraZeneca) for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).
News
The Food and Drug Administration (FDA) has approved a modification to the nivolumab (Opdivo; Bristol-Myers Squibb) dosage regimen for renal cell carcinoma, metastatic melanoma, and non-small cell lung cancer.
Drugs in the Pipeline
LOXO-292 is being evaluated in the ongoing Phase 1/2 LIBRETTO-001 clinical trial.
News
The FDA granted accelerated approval of Alunbrig, a kinase inhibitor, for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
News
Portrazza (necitumumab; Lillly Oncology) is now available through an exclusive specialty pharmacy provider Biologics, Inc.
